Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109631 - LAMININ IMMOBILIZATION, METHODS AND USES THEREOF

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

C L A I M S

1. A composition for substrate functionalization comprising:

a poly(ethylene glycol) - PEG - for binding to the substrate;

an agrin domain comprising a sequence at least 95% identical to SEQ. ID NO: 1 bound to said PEG;

a laminin able for binding to a bioactive agent;

wherein the laminin is bound to the agrin domain.

2. The composition according to any of the previous claim wherein the agrin domain comprises a sequence at least 96% identical to SEQ. ID NO: 1, preferably at least 97% identical to SEQ. ID NO: 1, at least 98% identical to SEQ. ID NO: 1, at least 99% identical to SEQ. ID NO: 1.

3. The composition according to any of the previous claim wherein the agrin domain comprises a sequence identical to SEQ. ID NO: 1.

4. The composition according to any of the previous claims wherein the agrin domain is conjugated at its N-terminal with an end-group functionalized polyethylene glycol), preferably a thiol-terminated PEG.

5. The composition according to any of the previous claims wherein the bioactive agent is selected from a list consisting of: a biomolecule, an active ingredient, a growth factor, extracellular vesicle, a hormone, a cell, or mixtures thereof.

6. The composition according to any of the previous claims wherein the biomolecule is another laminin, a different protein, a peptide, a drug, a polysaccharide, or mixtures thereof.

7. The composition according to any of the previous claims wherein the cell is selected from: osteoblast, osteoclast, osteocyte, pericyte, endothelial cells, endothelial progenitor cells, hematopoietic progenitor cell, hematopoietic stem cell, neural progenitor cell, neural stem cell, neural cell, oligodendrocyte progenitor cell, oligodendrocytes, ependymal cells, mesenchymal stromal/stem cell, induced pluripotent stem cell, embryonic stem cell, perivascular stem cells, amniotic fluid stem cell, amniotic membrane stem cell, umbilical cord stem cell, genetically engineered cell, or mixtures thereof.

8. The composition according to any of the previous claims wherein the poly(ethylene glycol) size varies between 2 and 40 kDa; preferably 3-20 kDa, more preferably 3.5-10 kDa .

9. The composition according to any of the previous claims for use in veterinary or human medicine.

10. The composition according to any of the previous claims, for use in the treatment of diseases that involve tissue regeneration or repair, or for use in the prevention of tissue degeneration.

11. The composition according to any of the previous claims, wherein the substrate is a naturally- derived or purely synthetic polymer, a synthetically-derived biopolymer, a metal, or combinations thereof.

12. A hydrogel comprising the composition described in any of the previous claims.

13. The hydrogel of the previous claim wherein the hydrogel is selected from the following list: poly(ethylene glycol), poly(vinyl alcohol), chitosan, collagen, alginate, dextran, fibrin, hyaluronic acid, silk fibroin, cellulose, synthetically-derived biopolymers, or mixtures thereof.

14. A substrate coating comprising the composition described in any of the previous claims.

15. A coated article comprising the coating of the previous claim.

16. The coated article of the previous claim wherein the article is an electrode.

17. A kit for screening therapeutic drugs comprising the composition described in any of the previous claims.